Drug Profile
CLL 442
Alternative Names: CLL442Latest Information Update: 17 Mar 2021
Price :
$50
*
At a glance
- Originator Novartis Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Squamous cell cancer
Most Recent Events
- 17 Mar 2021 No development reported - Phase-I/II for Squamous cell cancer (In the elderly, In adults) in USA, Australia, Belgium (Topical)
- 01 Nov 2018 Novartis completes a phase I/II trial in Squamous cell cancer (In adults, In the elderly) in Australia, Belgium, USA (NCT03333694) (EudraCT2017-003495-31)
- 15 Dec 2017 Phase-I/II clinical trials in Squamous cell cancer (In adults, In the elderly) in Australia, Belgium, USA (Topical) (NCT03333694)